title: What do the statin trials tell us?
abstract: The results of five large-scale, randomized, placebo-controlled trials, involving nearly 31,000 subjects, attest to the benefits of statins in the prevention of coronary events. Several key observations can be made on the basis of the evidence from these investigations. Of primary importance is the fact that statins reduce coronary event rates in patients with or without coronary heart disease. The percentage reduction in risk increases with each successive year of statin therapy. Moreover, the risk reduction is proportional to the reduction in low-density lipoprotein cholesterol. Subgroup analyses have demonstrated that the efficacy of statins extends to specific subgroups of patients, including women, people with diabetes, and older individuals. These agents also reduce the risk of stroke and transient ischemic attacks in patients with coronary disease. Both the randomized trials and widespread clinical experience have confirmed that statins are safe and do not increase the risk of cancer or mortality. Several markers of atherosclerotic risk are ameliorated by statins, although the clinical significance of this observation remains under investigation. The broad range of the therapeutic effects of statins yields safe, effective management of hypercholesterolemia in current practice while also providing a foundation for additional therapeutic refinements in the future.
authors.affiliation: Division of Cardiology, San Francisco General Hospital, University of California at San Francisco, 94110, USA. dwaters@medsfgh.ucsf.edu
authors.forename: D D
authors.initials: DD
authors.lastname: Waters
mesh_terms: D000367:Age Factors; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications / Q000517:prevention & control; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D012306:Risk
chemical_list: D000924:Anticholesteremic Agents; D000960:Hypolipidemic Agents